Hermann Einsele is the chair of the department of Internal Medicine II which runs one of the largest stem cell transplantation programs in Germany (>250 SCT/year) and plays an active role in national and international clinical trial networks in cellular immunotherapy for cancer. H. Einsele pioneered the use of immunotherapy with selected T cells in Europe and currently focuses on the use of antibody- and cell-based immunotherapy to treat residual tumors and infections esp. in patients undergoing allogeneic stem cell transplantation. Prof. Einsele is co-chair of the CRC/TR124 (Pathogenic fungi and their human host: Networks of interaction), PI of the EU-FP7 program NanoII, and coordinator of the EU-PF7 program T-Control and Era-Net PathogenoMics.
H. Einsele heads the clinical and translational research program on multiple myeloma in Würzburg. He chairs the Deutsche Studiengruppe Multiples Myelom (DSMM) including 40 centers in Germany and the Interdisciplinary Wilhelm Sander Therapy Unit for MM research and treatment at the CCCMF (Therapieeinheit Multiples Myelom: Risikoadaptierte Stratifizierung und interdisziplinäre Behandlung des Multiplen Myeloms). He is the speaker of the CRU216 (Characterization of the Oncogenic Signaling Network in Multiple Myeloma: Development of Targeted Therapies). In addition he is an active member of the EU FP7 funded consortium Optatio (Interaction between myeloma cells and the microenvironment).